CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
CVRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
CVRx, Inc.NASDAQ: CVRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 58.0% from a year ago
Total equity stood at $29.11M at the end of Q1 FY2026, down 58.0% from a year earlier and down 26.0% from the prior quarter. Over 3 fiscal years it compounded at -28.9% a year.
Context
- Total equity amounted to 29.2% of total assets at the end of Q1 FY2026, down 24.3 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -58.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 39.32M USD
- Year-over-year change
- -44.7%
- 4-year CAGR
- -28.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.32M | -44.7% |
| FY2024 | 2024-12-31 | 71.06M | -6.4% |
| FY2023 | 2023-12-31 | 75.95M | -30.4% |
| FY2022 | 2022-12-31 | 109.18M | -25.2% |
| FY2021 | 2021-12-31 | 145.96M | — |
Total Equity vs competitors
How CVRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -58.0% is the lowest of 10, against a peer median of -10.8%.
- Total equity amounts to 29.2% of total assets for CVRX, versus a peer median of 49.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $282.14M USD | -10.8% | -6.2% | 76.9% | |
| Mar 2026 | $145.8M USD | +6.6% | +13.9% | 73.9% | |
| Dec 2025 | $139.73M USD | -26.1% | -13.6% | 86.2% | |
| Mar 2026 | $134.17M USD | -15.8% | -9.0% | 71.9% | |
| Mar 2026 | $68.29M USD | +21.4% | -1.8% | 30.6% | |
| Mar 2026 | $53.9M USD | -30.6% | -26.4% | 49.1% | |
| Mar 2026 | €37.64M EUR | -55.9% | -9.5% | 38.0% | |
| Mar 2026 | $34.34M USD | -2.4% | — | 33.4% | |
| Mar 2026 | $29.11M USD | -58.0% | -28.9% | 29.2% | |
| Mar 2026 | $1.84M USD | +110.6% | — | 5.0% | |
| Peer median (excluding CVRX) | — | -10.8% | -9.0% | 49.1% | |
Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 142.07M | 106.19M | 90.57M | 105.93M | 75.71M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.56M | 5.5M | 7.55M | 9.27M | 10.67M |
| Inventory | 3.88M | 6.96M | 10.98M | 12.11M | 12.21M |
| Other Current Assets | 2.59M | 4.22M | 2.99M | 2.51M | 3.07M |
| Total Current Assets | 151.1M | 122.88M | 112.09M | 129.81M | 101.65M |
| Property, Plant & Equipment (Net) | 1.43M | 2.03M | 3.11M | 3.57M | 3.12M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 26K | 27K | 27K | 27K | 26K |
| Total Non-current Assets | 1.45M | 2.06M | 3.14M | 3.6M | 3.15M |
| Total Assets | 152.55M | 124.94M | 115.23M | 133.41M | 104.79M |
| Account Payables | 510K | 1.72M | 1.88M | 2.58M | 3.83M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 351K | 120K | 125K | 135K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.32M | 3.26M | 4.11M | 5.67M | 9.48M |
| Total Current Liabilities | 5.91M | 8.09M | 7.86M | 10.76M | 13.32M |
| Long-term Debt | 0 | 6.75M | 29.22M | 49.27M | 50.15M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 681K | 805K | 1.04M | 1.45M | 1.36M |
| Total Non-current Liabilities | 681K | 7.67M | 31.42M | 51.6M | 52.15M |
| Total Liabilities | 6.59M | 15.76M | 39.28M | 62.36M | 65.47M |
| Common Stock | 204K | 207K | 209K | 253K | 263K |
| Retained Earnings | (394.75M) | (436.18M) | (477.38M) | (537.35M) | (590.65M) |
| Accumulated OCI | (198K) | (207K) | (207K) | (206K) | (203K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 145.96M | 109.18M | 75.95M | 71.06M | 39.32M |
| Total Debt | 0 | 7.09M | 30.61M | 50.43M | 50.79M |
| Net Debt | (142.07M) | (99.11M) | (59.96M) | (55.5M) | (24.92M) |
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.